Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alphamab Oncology Ltd.
Industry Sector: HealthTechnology
CEO: Ting Xu, PhD
Number Of Employees: 420
Enterprise Value: $253,753,022
PE Ratio: 42.16
Exchange/Ticker 1: HKEX:9966
Exchange/Ticker 2: N/A
Latest Market Cap: $981,087,765
BioCentury | Oct 1, 2024
Deals
Prime narrows gene editing focus with BMS deal
Deals Report: Novartis-Generate use AI to develop protein therapies, and updates from Roche-Regor, CSPC-Alphamab and more
BioCentury | May 30, 2024
Product Development
Clinical Report: Phase III win for J&J in neuropsychiatry; Biohaven falls on BHV-1300 data
Plus: Insmed gets boost from bronchiectasis readout and updates from HI-Bio, Corcept, Tango and Ikena
BioCentury | Apr 23, 2022
Product Development
How biotechs are coping with lockdown in Shanghai
Staff at whitelisted companies living at their workplaces
BioCentury | Jan 8, 2022
Finance
Buysiders eye 2022 as the year of immuno-oncology’s next big act
High hopes for catalysts brewing for years have investors expecting a new era, and neurology may be on the upswing too
BioCentury | Dec 22, 2021
Product Development
PD-1’s new narrative – a bonanza of innovation
Half the field is stuck in first gear, but a wealth of bispecifics, novel technologies are bringing new energy
BioCentury | Dec 3, 2021
Management Tracks
Sniecinski becomes CBO at Praxis
Plus: Monte Rosa, Taro, Point, Harbour and more
BioCentury | Sep 24, 2021
Product Development
ESMO shifts the HER2 antibody landscape
How next-gen antibody innovation is driving advances in HER2-positive cancers
BioCentury | Sep 22, 2021
Management Tracks
CEO Anido out at Aerie after Phase II data
Plus: Sage, Gossamer Bio, Nimbus, Inventiva, Selecta and more
BioCentury | Sep 1, 2021
Management Tracks
Zaks joins board at Teva
Jogerst named CBO at Rubius, plus updates from Telix, Talis, Ziopharm, Pyxis and more
BioCentury | Jun 3, 2021
Product Development
ASCO21 data for bispecific checkpoints bode well for coming wave of therapies
As pipeline grows, early clinical readouts report at ASCO21
Items per page:
1 - 10 of 34